Hennion & Walsh Asset Management Inc. Reduces Stock Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS)

Hennion & Walsh Asset Management Inc. trimmed its holdings in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 1.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 13,678 shares of the company’s stock after selling 232 shares during the quarter. Hennion & Walsh Asset Management Inc.’s holdings in Krystal Biotech were worth $2,143,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also added to or reduced their stakes in the company. State Street Corp grew its stake in Krystal Biotech by 9.0% during the 3rd quarter. State Street Corp now owns 1,452,811 shares of the company’s stock valued at $264,455,000 after purchasing an additional 119,936 shares during the last quarter. Geode Capital Management LLC raised its holdings in Krystal Biotech by 2.0% in the 3rd quarter. Geode Capital Management LLC now owns 591,631 shares of the company’s stock worth $107,714,000 after purchasing an additional 11,411 shares during the period. Dimensional Fund Advisors LP raised its holdings in Krystal Biotech by 1.3% in the 2nd quarter. Dimensional Fund Advisors LP now owns 580,452 shares of the company’s stock worth $106,593,000 after purchasing an additional 7,537 shares during the period. Hood River Capital Management LLC raised its holdings in Krystal Biotech by 5.1% in the 2nd quarter. Hood River Capital Management LLC now owns 521,093 shares of the company’s stock worth $95,694,000 after purchasing an additional 25,507 shares during the period. Finally, Franklin Resources Inc. raised its holdings in Krystal Biotech by 34.2% in the 3rd quarter. Franklin Resources Inc. now owns 243,760 shares of the company’s stock worth $43,774,000 after purchasing an additional 62,178 shares during the period. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Krystal Biotech Trading Up 2.5 %

Shares of NASDAQ KRYS opened at $148.39 on Friday. The stock has a market cap of $4.27 billion, a P/E ratio of 83.84 and a beta of 0.85. Krystal Biotech, Inc. has a 12-month low of $107.50 and a 12-month high of $219.34. The business’s fifty day simple moving average is $170.98 and its 200-day simple moving average is $182.12.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings results on Monday, November 4th. The company reported $0.91 earnings per share for the quarter, beating analysts’ consensus estimates of $0.84 by $0.07. The company had revenue of $83.84 million for the quarter, compared to analysts’ expectations of $82.94 million. Krystal Biotech had a return on equity of 7.54% and a net margin of 21.68%. Krystal Biotech’s quarterly revenue was up 879.9% on a year-over-year basis. During the same period last year, the firm earned ($0.67) earnings per share. On average, equities analysts forecast that Krystal Biotech, Inc. will post 3.03 EPS for the current fiscal year.

Insiders Place Their Bets

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction dated Friday, December 13th. The stock was sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the transaction, the insider now owns 1,475,882 shares of the company’s stock, valued at approximately $243,195,835.96. This trade represents a 1.67 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 14.10% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have commented on KRYS. Chardan Capital reiterated a “buy” rating and set a $212.00 price objective on shares of Krystal Biotech in a research note on Wednesday, December 18th. HC Wainwright reiterated a “buy” rating and issued a $221.00 price objective on shares of Krystal Biotech in a research report on Wednesday, December 18th. Finally, Citigroup increased their price objective on Krystal Biotech from $204.00 to $206.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Krystal Biotech presently has a consensus rating of “Buy” and an average price target of $206.67.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).